Literature DB >> 27162674

Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis.

Seok Joo1, Dong Kwan Kim1, Hee Je Sim1, Geun Dong Lee1, Su Kyung Hwang1, Sehoon Choi1, Hyeong Ryul Kim1, Yong-Hee Kim1, Seung-Il Park1.   

Abstract

BACKGROUND: Lung cancer patients with idiopathic pulmonary fibrosis (IPF) are at a high risk of requiring lung resection. The optimal surgical strategy for these patients remains unclear. This study aimed to compare the clinical results of a sublobar resection versus a lobectomy or more extensive resection for lung cancer in patients with IPF.
METHODS: From January 1995 to December 2012, 80 patients with simultaneous non-small cell lung cancer and IPF were treated surgically at Asan Medical Center. Predictors of recurrence-free survival and overall survival were evaluated in the series.
RESULTS: Lobectomy or more extensive resection of the lung (lobar resection group) was performed in 65 patients and sublobar resection (sublobar resection group) was carried out in 15 patients. The sublobar resection group showed fewer in-hospital mortalities than the lobar resection group (6.7% vs. 15.4%; P=0.68). For late mortality after lung resection, cancer-related deaths were not significantly different in incidence between the two groups (55.6% vs. 30.6%; P=0.18). Recurrence-free survival after lung resection was significantly greater in the lobar than in the sublobar resection group (P=0.01). However, overall survival after lung resection was not significantly different between the two groups (P=0.05). Sublobar resection was not a significant predictive factor for overall survival (hazard ratio =0.50; 95% CI: 0.21-1.15; P=0.10).
CONCLUSIONS: Although not statistically significant, a sublobar resection results in less in-hospital mortality than a lobar resection for lung cancer patients with IPF. There is no significant difference in overall survival compared with lobar resection. A sublobar resection may be another therapeutic option for lung cancer patients with IPF.

Entities:  

Keywords:  Lung cancer; idiopathic pulmonary fibrosis (IPF); sublobar resection

Year:  2016        PMID: 27162674      PMCID: PMC4842788          DOI: 10.21037/jtd.2016.03.76

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  18 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Acute exacerbation of interstitial fibrosis after pulmonary resection.

Authors:  Mustafa Yüksel; Mehmet Oguzhan Ozyurtkan; Korkut Bostanci; Rengin Ahiskali; Nihat Kodalli
Journal:  Ann Thorac Surg       Date:  2006-07       Impact factor: 4.330

3.  Cumulative incidence of and predictive factors for lung cancer in IPF.

Authors:  Yuichi Ozawa; Takafumi Suda; Tateaki Naito; Noriyuki Enomoto; Dai Hashimoto; Tomoyuki Fujisawa; Yutaro Nakamura; Naoki Inui; Hirotoshi Nakamura; Kingo Chida
Journal:  Respirology       Date:  2009-07       Impact factor: 6.424

4.  Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases.

Authors:  Toshihiko Sato; Atsushi Watanabe; Haruhiko Kondo; Masato Kanzaki; Kenichi Okubo; Kohei Yokoi; Kazuya Matsumoto; Takashi Marutsuka; Hirohiko Shinohara; Satoshi Teramukai; Kazuma Kishi; Masahito Ebina; Yukihiko Sugiyama; Okumora Meinoshin; Hiroshi Date
Journal:  J Thorac Cardiovasc Surg       Date:  2014-09-18       Impact factor: 5.209

5.  Predictive factors for postoperative acute exacerbation of interstitial pneumonia combined with lung cancer.

Authors:  Yasushi Shintani; Mitsunori Ohta; Teruo Iwasaki; Naoki Ikeda; Emiko Tomita; Kunimitsu Kawahara; Yuko Ohno
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-04-18

6.  Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes.

Authors:  Masako Chiyo; Yasuo Sekine; Takekazu Iwata; Koichiro Tatsumi; Kazuhiro Yasufuku; Akira Iyoda; Mizuto Otsuji; Shigetoshi Yoshida; Kiyoshi Shibuya; Toshihiko Iizasa; Yukio Saitoh; Takehiko Fujisawa
Journal:  J Thorac Cardiovasc Surg       Date:  2003-10       Impact factor: 5.209

7.  Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication?

Authors:  Toshio Fujimoto; Tsuyoshi Okazaki; Tadashi Matsukura; Takeshi Hanawa; Naoki Yamashita; Koichi Nishimura; Masayoshi Kuwabara; Yoshito Matsubara
Journal:  Ann Thorac Surg       Date:  2003-11       Impact factor: 4.330

8.  Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis.

Authors:  Hidenori Kawasaki; Kanji Nagai; Junji Yoshida; Mitsuyo Nishimura; Yutaka Nishiwaki
Journal:  J Surg Oncol       Date:  2002-09       Impact factor: 3.454

9.  Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?

Authors:  Atsushi Watanabe; Tetsuya Higami; Syunsuke Ohori; Tetsuya Koyanagi; Shinji Nakashima; Tohru Mawatari
Journal:  J Thorac Cardiovasc Surg       Date:  2008-09-24       Impact factor: 5.209

10.  Clinical analysis of interstitial pneumonia after surgery for lung cancer.

Authors:  Taku Okamoto; Masashi Gotoh; Daiki Masuya; Takashi Nakashima; Dage Liu; Kotaro Kameyama; Shinya Ishikawa; Yasumichi Yamamoto; Cheng-Long Huang; Hiroyasu Yokomise
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-07
View more
  6 in total

Review 1.  Measuring Surgery Outcomes of Lung Cancer Patients with Concomitant Pulmonary Fibrosis: A Review of the Literature.

Authors:  Taichiro Goto
Journal:  Cancers (Basel)       Date:  2018-07-04       Impact factor: 6.639

2.  Developmental Stage-Specific Distribution of Macrophages in Mouse Mammary Gland.

Authors:  Teneale A Stewart; Katherine Hughes; David A Hume; Felicity M Davis
Journal:  Front Cell Dev Biol       Date:  2019-10-24

3.  [Characteristics and Influencing Factors of Pathogenic Bacteria in Lung Cancer Chemotherapy Combined with Nosocomial Pulmonary Infection].

Authors:  Qiuhong Bao; Hua Zhou; Xi Chen; Qing Yang; Jianying Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-12-20

4.  Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics.

Authors:  Feng Yan; Zhensong Wen; Rui Wang; Wenling Luo; Yufeng Du; Wenjun Wang; Xianyang Chen
Journal:  BMC Pulm Med       Date:  2017-12-06       Impact factor: 3.317

5.  High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery.

Authors:  Shun Takao; Takeshi Masuda; Kakuhiro Yamaguchi; Shinjiro Sakamoto; Yasushi Horimasu; Taku Nakashima; Shintaro Miyamoto; Hiroshi Iwamoto; Kazunori Fujitaka; Hironobu Hamada; Noboru Hattori
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

Review 6.  Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis.

Authors:  Elena Bargagli; Rosa Metella Refini; Miriana d'Alessandro; Laura Bergantini; Paolo Cameli; Lorenza Vantaggiato; Luca Bini; Claudia Landi
Journal:  Int J Mol Sci       Date:  2020-08-07       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.